• 1
    Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998; 41: 134355.
  • 2
    Davis MA, Ettinger WH, Neuhaus JM, Mallon KP. Knee osteoarthritis and physical functioning: evidence from the NHANES I epidemiologic followup study. J Rheumatol 1991; 18: 5918.
  • 3
    Badley EM. The effect of osteoarthritis on disability and health care use in Canada. J Rheumatol 1995; 22 Suppl 43: 1922.
  • 4
    Yelin EH, Katz PP. Labor force participation among persons with musculoskeletal conditions, 1970–87. Arthritis Rheum 1991; 34: 136170.
  • 5
    Gabriel SE, Crowson CS, O'Fallon WM. Costs of osteoarthritis: estimates from a geographically defined population. J Rheumatol 1995; 22 Suppl 43: 235.
  • 6
    Gabriel SE, Crowson CS, Campoin ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997; 24: 438.
  • 7
    March LM, Bachmeier CJM. Economics of osteoarthritis: a global perspective. Clin Rheumatol 1997; 11: 81734.
  • 8
    Badley EM, Crotty M. An international comparison of the estimated effect of the aging of the population on the major cause of disablement, musculoskeletal disorders. J Rheumatol 1995; 22: 193440.
  • 9
    Crolle G, D'Este E. Glucosamine sulphate for the management of arthrosis: a controlled clinical investigation. Curr Med Res Opin 1980; 7: 1049.
  • 10
    Pujalte JM, Llavore EP, Ylescupidez FR. Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Opin 1980; 7: 1104.
  • 11
    Drovanti A, Bignamini AA, Rovati AL. Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther 1980; 3: 26072.
  • 12
    D'Ambrosio E, Casa B, Bompani R, Scali G, Scali M. Glucosamine sulphate: a controlled clinical investigation in arthrosis. Pharmatherapeutica 1981; 2: 5048.
  • 13
    Lopez Vas A. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee on out-patients. Curr Med Res Opin 1982; 8: 1459.
  • 14
    Reichelt A, Forster KK, Fischer FM, Rovati LC, Setnikar I. Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee: a randomised, placebo-controlled, double-blind study. Arzneimittelforschung 1994; 44: 7580.
  • 15
    Noack W, Fischer M, Forster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 519.
  • 16
    Müller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikar I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994; 2: 619.
  • 17
    Qiu GX, Gao SN, Giacovelli G, Rovati L, Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. Arzneimittelforschung 1998; 48: 46974.
  • 18
    Houpt JB, McMillan R, Paget-Dellio D, Russell A, Gahunia HK. Effect of glucosamine hydrochloride (GHcl) in the treatment of pain of osteoarthritis of the knee. J Rheumatol 1999; 26: 242330.
  • 19
    Rindone JP, Hiller D, Collacott E, Nordhaugen N, Arriola G. Randomized, controlled trial of glucosamine for treating osteoarthritis of the knee. West J Med 2000; 172: 914.
  • 20
    Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology 2002; 41: 27984.
  • 21
    McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 146975.
  • 22
    Cibere J, Esdaile JM. Glucosamine use in osteoarthritis: what is the evidence for its efficacy [abstract]? J Rheumatol 1999; 26: 1628.
  • 23
    Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 2516.
  • 24
    Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 211323.
  • 25
    McAlindon T. Why are clinical trials of glucosamine no longer uniformly positive? Rheum Dis Clin North Am 2003; 29: 789801.
  • 26
    Kopec JA, Abrahamowicz M, Esdaile JM. Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol 1993; 46: 95971.
  • 27
    Altman RD, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986; 29: 103949.
  • 28
    Kellgren JH, Lawrence JS. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957; 16: 494502.
  • 29
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important participant relevant outcomes to antirheumatic drug therapy in participants with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 30
    The EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199208.
  • 31
    Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 2000; 27: 263541.
  • 32
    Dougados M, LeClaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. A report of the Osteoarthritis Research Society International Standing Committee for clinical trials response criteria initiative. Osteoarthritis Cartilage 2000; 8: 395403.